Glucose tetrasaccharide (Glc4) is used as a reference in analysis of urinary glucose tetrasacchaide, a biomarker for Pompe disease and other glycogen storage diseases.
Conditionnement
Bottomless glass bottle. Contents are inside inserted fused cone.
Autres remarques
To gain a comprehensive understanding of our extensive range of Monosaccharides for your research, we encourage you to visit our Carbohydrates Category page.
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Équipement de protection individuelle
Eyeshields, Gloves, type N95 (US)
Faites votre choix parmi les versions les plus récentes :
Pompe disease is an autosomal recessive disorder caused by deficiency of the lysosomal enzyme, acid alpha-glucosidase (GAA). To the best of our knowledge, no studies have reported the results of systematic and sequential CT analyses before and during ERT. In
Journal of immunological methods, 48(1), 109-119 (1982-01-01)
A radioimmunoassay is described that allows rapid determination of a urinary oligosaccharide -- Glc alpha 1-6Glc alpha 1-4Glc alpha 1-4Glc [(Glc)4] -- at concentrations greater than 2 pmol/microliter. Antibodies produced in rabbits immunized with the phenethylamine derivative of (Glc)4 coupled
Unique oligosaccharide (apparently glucotetrasaccharide) in urine of patients with glycogen storage diseases.
Journal of neuroimmunology, 217(1-2), 95-101 (2009-11-03)
The serum level of IgM antibodies against Glc(alpha1,4)Glc(alpha) (GAGA4) is higher in relapsing remitting multiple sclerosis (RRMS) compared to other neurological disease (OND) patients and healthy controls (HC). Detecting the level of anti-GAGA4 antibody by enzyme immunoassay and total IgM
Genetics in medicine : official journal of the American College of Medical Genetics, 21(4), 887-895 (2018-09-15)
To investigate immune tolerance induction with transient low-dose methotrexate (TLD-MTX) initiated with recombinant human acid α-glucosidase (rhGAA), in treatment-naïve cross-reactive immunologic material (CRIM)-positive infantile-onset Pompe disease (IOPD) patients. Newly diagnosed IOPD patients received subcutaneous or oral 0.4 mg/kg TLD-MTX for 3
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
